Cargando…
Treatment of an HLH-mimic disease based on HAVCR2 variants with absent TIM-3 expression
[Figure: see text]
Autores principales: | Tromp, Samantha A.M., Gillissen, Marijn A., Bernelot Moens, Sophie J., van Leeuwen, Ester M.M., Jansen, Machiel H., Koens, Lianne, Rutten, Caroline E., Kuijpers, Taco W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636311/ https://www.ncbi.nlm.nih.gov/pubmed/35588499 http://dx.doi.org/10.1182/bloodadvances.2022007450 |
Ejemplares similares
-
Functional variants of TIM-3/HAVCR2 3′UTR in lymphoblastoid cell lines
por: Pu, Feifei, et al.
Publicado: (2018) -
TIM1 (HAVCR1) Is Not Essential for Cellular Entry of Either Quasi-enveloped or Naked Hepatitis A Virions
por: Das, Anshuman, et al.
Publicado: (2017) -
Opposing regulatory functions of the TIM3 (HAVCR2) signalosome in primary effector T cells as revealed by quantitative interactomics
por: Zhai, Yunhao, et al.
Publicado: (2020) -
B-cell targeting with anti-CD38 daratumumab: implications for differentiation and memory responses
por: Verhoeven, Dorit, et al.
Publicado: (2023) -
Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma
por: Holderried, Tobias A. W., et al.
Publicado: (2019)